IGC Pharma Reports $0.32 Million in Third-Quarter Revenue

IGC Pharma, Inc. reported third-quarter revenue of $0.32 million and a wider net loss attributable to common stockholders. Third-quarter revenue was $0.32 million. Net loss attributable to common stockholders widened to $2.046 million from $1.821 million. Basic and diluted net loss per share was 2 cents. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.